Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeneDx Holdings Corp. (WGS) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. GeneDx is a Delaware‑incorporated company whose Class A common stock trades on The Nasdaq Stock Market under the symbol WGS, with related warrants trading under WGSWW, as noted in its current reports on Form 8‑K.
Investors and analysts can use this page to review current reports on Form 8‑K, which for GeneDx have included announcements of quarterly financial results, updated guidance, and significant corporate events such as board appointments and annual meeting outcomes. These filings offer detail on revenue composition, exome and genome test volumes, margin metrics, cash position, and shareholder voting results, as described in the company’s earnings‑related 8‑K filings.
Because GeneDx positions itself as a global leader in rare disease diagnosis and rare disease genomics, its periodic and current reports are a key source for understanding how its genomic testing business, GeneDx Infinity dataset, and related initiatives translate into financial performance and corporate governance decisions. Filings also disclose information about securities such as its warrants, including listing details and exercise price.
On Stock Titan, SEC documents are paired with AI‑powered summaries that help explain the contents of lengthy filings in accessible language. Users can quickly see the main points from GeneDx’s 8‑K disclosures, and, where applicable, locate information related to quarterly and annual reporting, capital structure, and significant events affecting WGS shareholders. Real‑time updates from EDGAR ensure that new GeneDx filings appear promptly, while AI‑generated highlights make it easier to navigate complex regulatory documents.
Katherine Stueland, Chief Executive Officer and a director of GeneDx Holdings Corp. (WGS), reported multiple sales of Class A common stock on 09/30/2025 under a preexisting Rule 10b5-1 trading plan adopted August 16, 2024. The Form 4 shows eight separate sale entries that together reduced her direct beneficial holdings from 13,972 shares to 1,720 shares held directly after the transactions. Reported weighted-average prices for the sales ranged from about $104.98 to $112.04 per share.
The filing discloses that, in addition to the 1,720 directly held shares, Ms. Stueland beneficially owns restricted stock units convertible into up to 444,539 shares and options to purchase up to 107,610 shares that vest according to their terms. The transactions were executed pursuant to the 10b5-1 plan and the Form 4 was signed by an attorney-in-fact on 10/01/2025.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported multiple transactions in the company’s Class A common stock on 09/30/2025. Mr. Feeley acquired 1,246 shares via exercise of employee stock options at an exercise price of $32.67 and sold a series of shares in multiple transactions under a Rule 10b5-1 trading plan adopted August 21, 2024. The reported sales totaled 7,609 shares across weighted-average prices ranging from about $104.98 to $113.68, leaving the reporting person with 3,392 shares beneficially owned. The filing discloses outstanding RSUs for up to 124,633 shares and options for up to 25,906 shares that vest over time.
Form 144 notice for GeneDx Holdings Corp. (WGS) shows proposed and recent sales of Class A Common Stock by an individual identified in the filing. Two broker-assisted proposed sales are reported for 09/30/2025: 16,425 shares through Morgan Stanley Smith Barney (aggregate market value $1,769,600) and 12,858 shares through Merrill Lynch (aggregate market value $1,390,912). The filing lists the securities as acquired by the seller as restricted stock units on 05/02/2022, 12/09/2022 and 04/26/2023, with acquisition amounts of 3,902, 6,575 and 18,806 shares respectively.
The filing also discloses actual sales by Katherine Stueland during the past three months totaling 29,189 shares for gross proceeds of $3,148,332. The company outstanding share count reported in the notice is 28,726,248, and the proposed combined aggregate market value of the planned sales is $3,160,512.
Thomas Fuchs, a director of GeneDx Holdings Corp. (ticker shown as WGS), was granted 3,438 restricted stock units (RSUs) on 09/17/2025. Each RSU converts into one share of Class A Common Stock for no consideration when settled. The award vests in three equal installments on 09/17/2026, 09/17/2027, and 09/17/2028, subject to the reporting persons continued service. Following the grant, the reporting person beneficially owns 3,438 shares of Class A Common Stock as a direct owner. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
Thomas Fuchs filed an initial Form 3 reporting his relationship to GeneDx Holdings Corp. (ticker: WGS) as a Director. The event date triggering the filing is 09/17/2025. The form states that no securities are beneficially owned by the reporting person. The filing is signed on behalf of Mr. Fuchs by Bridget Brown, Attorney-in-Fact dated 09/19/2025.
Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp. amended a Form 4 to correct a typographical error and to report the vesting and acquisition of restricted stock units. The amendment clarifies that on 09/16/2025 Mr. Feeley acquired 7,197 restricted stock units, each convertible into one share of Class A common stock for no consideration, increasing his beneficial ownership to 12,483 shares.
The filing notes the original Form 4 filed on 09/18/2025 incorrectly showed a disposition code where an acquisition code was intended; no other line items were changed. The amendment is signed by an attorney-in-fact on behalf of the reporting person.
GeneDx Holdings Corp. (WGS) Form 4 shows Chief Financial Officer Kevin Feeley reported transactions on 09/16/2025 related to the vesting and settlement of restricted stock units (RSUs). 7,197 RSUs were treated as vested and settled for no cash consideration, and the Reporting Person triggered a sell-to-cover transaction that sold 3,728 shares at a weighted average price of $121.4727 to satisfy tax withholding. After these transactions, Mr. Feeley directly beneficially owned 8,755 shares of Class A common stock.
In addition to direct holdings, the filing discloses contingent rights to receive 124,633 RSU shares and options to purchase 27,152 shares, which vest over time per their terms. The sale is described as non-discretionary and solely to cover withholding obligations.
Insider transactions reported for GeneDx Holdings Corp. (WGS) show Katherine Stueland received 18,750 restricted stock units (RSUs) on 09/16/2025 that convert to Class A common stock for no cash consideration upon settlement, and sold 10,501 shares of Class A common stock the same day at a weighted-average price of $121.4727 per share as part of a block trade. The sale was disclosed as a "sell to cover" transaction to satisfy tax withholding tied to the RSU vesting and was not discretionary. After these transactions the reporting person directly beneficially owned 14,578 shares of Class A common stock and, separately, beneficially owned RSUs representing up to 444,539 shares and options for 107,610 shares, subject to their vesting terms.
GeneDx Holdings Corp. reported that its Board of Directors appointed Thomas Fuchs, Dr.sc. as a Class I director, effective September 17, 2025. His term will run until the company’s 2028 Annual Meeting of Stockholders, and the Board size increased from seven to eight directors with this appointment.
Dr. Fuchs is the SVP and Chief AI Officer at Eli Lilly and Company, where he leads artificial intelligence initiatives across drug discovery, clinical trials, manufacturing, commercial activities, and internal functions. He has previously held senior academic and research roles in AI and computational pathology and founded several companies, including Paige AI.
Under GeneDx’s Non-Employee Director Compensation Policy, Dr. Fuchs will receive an initial restricted stock unit grant valued at $420,000, vesting over three years, subject to his continued service. The company also plans to enter into its standard form indemnity agreement with him, and there are no related-party transactions requiring disclosure in connection with his appointment.
Katherine Stueland, Chief Executive Officer and Director of GeneDx Holdings Corp. (WGS), reported transactions on 09/09/2025 showing settlement of 6,546 RSUs for no consideration and contemporaneous sales to cover tax withholding. The Form 4 shows two sales: 3,639 shares at $128.05 and 18 shares at $129.079, leaving the reporting person with 6,329 shares of Class A common stock beneficially owned.
In addition to those shares, the filing discloses contingent rights to 463,289 RSUs and options to purchase 107,610 shares, which vest per their terms. The RSUs vested at 6.25% quarterly starting March 9, 2023. The report was signed by attorney-in-fact on 09/11/2025.
FAQ
What is the current stock price of GeneDx Holdings (WGS)?
What is the market cap of GeneDx Holdings (WGS)?
